The primary analysis showed that inhibition of PCSK9 was associated with a significantly lower risk of SLE [odds ratio (OR) 0.51, 95%CI 0.34 to 0.76, p = 0.001] in the European population. Here, PCSK9 is linked to systemic lupus erythematosus.